The Food and Drug Administration on Monday approved talazoparib (Talzenna, made by Pfizer) in combination with enzalutamide (Xtandi) for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair, or HRR, gene mutations, the agency said. The mutations must be detected by an FDA-authorized test, and the agency said it had previously approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for the combination. The approval expands an indication that was previously limited to HRR-mutated metastatic castration-resistant prostate cancer, which the FDA approved in 2023, according to Pfizer and Fierce Pharma (opens in new tab). Fierce Pharma (opens in new tab) described Talzenna as now the first PARP inhibitor approved by the FDA for metastatic hormone-sensitive prostate cancer.
The FDA based the decision on TALAPRO-3, a randomized, double-blind, placebo-controlled trial of 599 patients with HRR-mutated disease, the agency said. All patients received continuous androgen deprivation therapy and enzalutamide, plus either talazoparib or a placebo. The major efficacy measure was radiographic progression-free survival, assessed by the investigators. The FDA said median progression-free survival was not reached with talazoparib and 45.8 months with placebo, with a hazard ratio of 0.48 (95% confidence interval 0.36 to 0.65; p<0.0001). The agency said overall survival data were immature at the time of that analysis.
CancerNetwork (opens in new tab) reported that the results were presented at the American Society of Clinical Oncology’s 2026 annual meeting and published in the New England Journal of Medicine. In patients with BRCA mutations, the hazard ratio was 0.368, with median progression-free survival not reached versus 35.1 months on placebo, the outlet reported. In patients without BRCA mutations, the hazard ratio was 0.567. An interim look at overall survival showed a trend toward improvement that did not reach statistical significance (P = .0905), CancerNetwork (opens in new tab) said. Pharmaceutical Technology (opens in new tab) and Fierce Pharma (opens in new tab) both put the reduction in the risk of radiographic progression or death at 52%.
Neal Shore, medical director of the Carolina Urologic Research Center and a TALAPRO-3 investigator, told CancerNetwork (opens in new tab) that the survival curves “separate very early, within a matter of a few months.” In Pfizer’s news release on the approval, Neeraj Agarwal, co-director of the Prostate Cancer Program at the Harvard Cancer Consortium and the trial’s global lead investigator, called the approval “a critical advancement for patients with newly diagnosed metastatic prostate cancer with HRR gene mutations, who face a more aggressive disease, worse prognosis and limited treatment options.”
CancerNetwork (opens in new tab) reported that the combination’s safety profile matched that of each drug alone and that no new safety signals were identified. Anemia occurred in 71% of patients on talazoparib versus 22% on placebo, and grade 3 or higher anemia in 51% versus 3%, the outlet reported. Pfizer’s release said 5% of patients discontinued talazoparib because of anemia. The prescribing information carries warnings for myelodysplastic syndrome and acute myeloid leukemia, myelosuppression and embryo-fetal toxicity, the FDA said.
The recommended talazoparib dose is 0.5 mg by mouth once daily with enzalutamide until disease progression or unacceptable toxicity, the FDA said. Patients should also receive a GnRH analog or have had a bilateral orchiectomy. The FDA said it reviewed the application under Project Orbis with Australia’s Therapeutic Goods Administration and Health Canada, whose reviews are still under way, and that the application received priority review.
Fierce Pharma (opens in new tab) noted that in mid-2025 an FDA advisory committee voted unanimously against expanding the combination to castration-resistant patients regardless of HRR status, and that analysts at RBC Capital Markets expected the new approval to have a “negligible” effect on Pfizer’s bottom line. Talzenna brought in $107 million in the first half of 2026, the outlet said.